Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma

Medical Oncology

Volumn 17, Issue 1, 2000, Pages 2-15

  Hajek R ^b   Butch, A W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Dendritic cells; Immunotherapy; Multiple myeloma; Vaccination

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; PARAPROTEIN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CANCER REGRESSION; CANCER THERAPY; CELL CULTURE; CELL SUBPOPULATION; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0034062170     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02826210     Document Type: Review

References (104)

1. 1 Österborg A et al. Generation of T cell clones binding F(ab′)2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 1991; 34: 157-162.
2. 2 Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996; 24: 859-862.
3. 3 Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-135.
4. 4 Romani N et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137-151.
5. 5 Maraskovsky E et al. Dramatic increase in the numbers of dendritic cells in the peripheral blood of healthy volunteers treated with Flt3L. In: Wagner H et al (eds). Proceedings of 13th Eur Immunol Meeting 1997, Amsterdam: Elsevier, p 202.
6. 6 Rissoan MC et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-1186.
7. 7 Barlogie B et al. Advances in the treatment of multiple myeloma. Adv Int Med 1998; 43: 279-320.
8. 8 Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med 1973; 137: 1142-1161.
9. 9 Hart DNJ et al. Localization of HLA-ABC and DR antigens in human kidney. Transplantation 1981; 31: 428-433.
10. 10 Galy A, Morel F, Hill B, Chen BP. Hematopoietic progenitor cells of lymphocytes and dendritic cells. J Immunother 1998; 21: 132-141.
11. 11 Caux C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90: 1458-1470.
12. 12 Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-3287.
13. 13 Williams LA, Egner W, Hart DN. Isolation and function of human dendritic cells. Int Rev Cytol 1994; 153: 41-103.
14. 14 Sallusto F, Cella M, Daniel C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
15. 15 Melichar B, Savary C, Kudelka A P, Verschraegen C, Kavanagh J. Lineage-negative human leukocyte antigen-DR + cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998; 4: 799-809.
16. 16 O'Doherty U et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487-493.
17. 17 Austyn JM, Larsen CP. Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation 1990; 49: 1-7.
18. 18 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
19. 19 Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 1997; 158: 4543-4547.
20. 20 Fossum S. Lymph-borne dendritic leucocytes do not recirculate, but enter the lymph node paracortex to become interdigitating cells. Scand J Immunol 1988; 27: 97-105.
21. 21 Kupiec-Weglinski JW, Austyn JM, Morris PJ. Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues. J Exp Med 1988; 167: 632-645.
22. 22 Lardon F et al. Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1. Immunology 1997; 91: 553-559.
23. 23 Saraya K, Reid CD. Stem cell factor and the regulation of dendritic cell production from CD34+ progenitors in bone marrow and cord blood. Br J Haematol 1996; 93: 258-264.
24. 24 Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995; 154: 5851-5861.
25. 25 Caux C et al. Interleukin-3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells from cord blood CD34+ hema-topoietic progenitor cells. Blood 1996; 87: 2376-2385.
26. 26 Caux C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. J Exp Med 1996; 184: 695-706.
27. 27 Bernhard H et al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995; 55: 1099-1104.
28. 28 Herbst B et al. CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Brit J Haematol 1997; 99: 490-499.
29. 29 Lopez M et al. IL-13 induces CD34+ cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells. J Immunol Methods 1997; 208: 117-129.
30. 30 Mackensen A et al. Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood 1995; 86: 2699-2707.
31. 31 Strunk D, Rappersberger K, Egger C, Strobl H, Kromer E. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87: 1292-1302.
32. 32 Fearnley DB, McLellan AD, Mannering SI, Hock BD, Hart DN. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997; 89: 3708-3716.
33. 33 Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990; 85: 955-961.
34. 34 Pfeiffer S, Apperley JF, Goldschmidt H, Gooding RP. Ex vivo generation and function of dendritic cells in multiple myeloma. Biochem Soc Trans 1997; 25: 364.
35. 35 Chapuis F et al. Differentialion of human dendritic cells from monocytes in vitro. Eur J Immunol 1997; 27: 431-441.
36. 36 Szabolcs P et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 1996; 87: 4520-4530.
37. 37 Romani N et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
38. 38 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.
39. 39 Pickl WF et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 1996; 157: 3850-3859.
40. 40 Jansen JH et al. Inhibition of human colony foramation by interleukin 4. J Exp Med 1989; 170: 577-582.
41. 41 Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
42. 42 Santiago-Schwarz F, Divaris N, Kay C, Carsons SE. Mechanisms of tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-induced dendritic cell development. Blood 1993; 82: 3019-3028.
43. 43 Chen BG et al. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhacing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 1998; 91: 4652-4661.
44. 44 Brossart P et al. Generation of human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92, 11: 4238-4247.
45. 45 McKenzie ANJ, Culpepper JA, de Waal M, Briere R. Interleukin 13, a T cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993; 90: 3735-3739.
46. 46 Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1995; 182: 1111-1119.
47. 47 Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 1996; 157: 1499-1507.
48. 48 Maraskovsky E et al. The effect of Flt3 ligand and/or c-kit ligand on the generation of dendritic cells from human CD34+ bone marrow. Blood 1996; 88 (Suppl): S159 (abstract).
49. 49 Soligo D, et al. Expansion of dendritic cells derived from human CD34+ cells in static and continuous perfusion cultures. Br J Haematol 1998; 101: 352-363.
50. 50 Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772-4780.
51. 51 Ye Z et al. In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cells. Bone Marrow Transplant 1996; 18: 997-1008.
52. 52 Cella M et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin 12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996, 184: 747-785.
53. 53 Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Nat Acad Sci USA 1996; 93: 2588-2592.
54. 54 Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997; 90: 3640-3646.
55. 55 O'Doherty U et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993; 178: 1067-1076.
56. 56 Labeur MS et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168-175
57. 57 Mackey MF et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161: 2094-2098.
58. 58 Tarte K et al. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood 1998; 91: 1852-1857.
59. 59 Tarte K et al. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood 1997; 90: 3482-3495.
60. 60 Makino M, Baba M. A cryopreservation method of human peripheral blood mononuclear cells for efficient production of dendritic cells. Scand J Immunol 1997; 45: 618-622.
61. 61 Taylor MJ, London NJ, Thirdborough SM, Lake SP, James RF. The cryobiology of rat and human dendritic cells: preservation and destruction of membrane integrity by freezing. Cryobiology 1990; 27: 269-278.
62. 62 Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-787.
63. 63 Romani N et al. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989; 169: 1169-1178.
64. 64 Yang S, Darrow TL, Vervaert CE, Seigler HF. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell Immunol 1997; 179: 84-95.
65. 65 Choudhury A et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142
66. 66 Knight SC et al. Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 1998; 28: 1636-1644.
67. 67 Zitvogel L et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
68. 68 Bohlen H, Titzer S, Christensen O, Manzke O. Dendritic cell based idiotype vaccination in multiple myeloma. Blood 1997; 90 (Suppl): S579 (abstract).
69. 69 Hsu FJ et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
70. 70 Reichardt VL et al. Idiotype vaccination using dendritic autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-2419.
71. 71 Everson MP et al. Dendritic cells from different tissues induce production of different T cell cytokine profiles. J Leukocyte Biology 1996; 59: 494-498.
72. 72 Caux C et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272
73. 73 Wong BR et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-2080.
74. 74 Godiska R et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185: 1595-1604.
75. 75 Heufler C et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-668.
76. 76 Arpinati M, Loken M, Anasetti C. G-CSF mobilizes 2-dendritic cells rather than type 1-dendritic cells. Blood 1998; 92 (Suppl): S111 (abstract).
77. 77 Haug JS et al. Mobilization of CD80+ dendritic cells into the peripheral circulation by GM-CSF but not G-CSF. Blood 1998; 92 (Suppl): S444 (abstract).
78. 78 Hájek R, Adam Z, Váŝová I, Král Z. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Acta Med Austriaca 1996; 23: 85-91.
79. 79 Dabadghao S et al. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998; 100: 647-654.
80. 80 Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-1031.
81. 81 Kwak LW et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-1020.
82. 82 Kwak LW et al. T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 1997; 90 (Suppl): S579 (abstract).
83. 83 Battaglio S, Napoli P, Beggiato E, Borrione P. Development of vaccines against autologous tumor-derived idiotype in human myeloma: rationale and preparation. Minerva Biotec 1996; 8: 1-8.
84. 84 Massaia M, Pileri A. T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells? Leuk Lymphoma 1995; 17: 63-70.
85. 85 Stevenson FK, Link ChJ, Traynor A, Yu H, Corr M. DNA vaccination against multiple myeloma. Semin Hematol 1999; 36 (Suppl): S38-S42.
86. 86 Bergenbrant S, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996; 92: 840-846.
87. 87 Österborg A et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CDS - and CD4-specific T-cell responses. Blood 1998; 91: 2459-2466.
88. 88 Pfeiffer S et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol 1997; 98: 973-982.
89. 89 Choi D et al. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 1998; 4: 2709-2716.
90. 90 Lim HS, Bailey-Wood R. Id-pulsed dendritic cell vaccination in multiple myeloma. Blood 1998; 92 (Suppl): S108 (abstract).
91. 91 Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998; 4: 957-962.
92. 92 MacKenzie M, Strang G, Peshwa M, Sopapan J, Valone F. Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma. Blood 1998; 92 (Suppl): S108 (abstract).
93. 93 Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139-145.
94. 94 Lokhorst HM, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
95. 95 Tricot G et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
96. 96 Benyunes MC et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995; 16: 283-288.
97. 97 Massumoto C et al. Close stimulation of acute graft-versus host disease by interleukin-2 administered after autologous bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 1996; 17: 351-356.
98. 98 Giralt S et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-673.
99. 99 Beaujeaun F et al. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin-2 patients with acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 15: 691-696.
100. 100 Klingemann HG et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396.
101. 101 Meehan KR et al. A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies. J Hematother 1997; 6: 457-464.
102. 102 Rosenzwajg M, Camus S, Guigon M, Gluckman JC. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol 1998; 26: 63-72
103. 103 Siena S et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995; 23: 1465-1473.
104. 104 Cull G, Durrant L, Haynes A, Russell N. Generation of idiotype-specific immune responses following vaccination with autologous paraprotein pulsed dendritic cells in myeloma. Blood 1998; 92 (Suppl): S4187 (abstract).